Replimune Group, Inc. (REPL)
NASDAQ: REPL · Real-Time Price · USD
15.67
+0.37 (2.42%)
Sep 1, 2026, 4:00 PM EDT - Market closed
Replimune Group Market Cap
Replimune Group has a market cap or net worth of $1.48 billion as of September 2, 2026. Its market cap has increased by 250.28% in one year.
Market Cap
1.48B
Enterprise Value
1.39B
1-Year Change
250.28%
Ranking
Category
Stock Price
$15.67
ChartMarket Cap Chart
Since July 20, 2018, Replimune Group's market cap has increased from $467.50M to $1.48B, an increase of 215.81%. That is a compound annual growth rate of 15.21%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 1, 2026 | 1.48B | 93.63% |
| Dec 31, 2025 | 762.50M | -7.97% |
| Dec 31, 2024 | 828.50M | 66.40% |
| Dec 29, 2023 | 497.90M | -63.20% |
| Dec 30, 2022 | 1.35B | 6.46% |
| Dec 31, 2021 | 1.27B | -27.53% |
| Dec 31, 2020 | 1.75B | 281.78% |
| Dec 31, 2019 | 459.30M | 45.58% |
| Dec 31, 2018 | 315.50M | -32.51% |
| Jul 20, 2018 | 467.50M | - |
View and export this data all the way back to 2018. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Innoviva | 1.50B |
| First Tracks Biotherapeutics | 1.49B |
| Tyra Biosciences | 1.49B |
| ArriVent BioPharma | 1.48B |
| Maze Therapeutics | 1.48B |
| Apnimed | 1.45B |
| Aktis Oncology | 1.44B |
| Cullinan Therapeutics | 1.42B |